Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up.
Papadimitrakopoulou
V A
VA
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4096, USA.
Hong
W K
WK
Lee
J S
JS
Martin
J W
JW
Lee
J J
JJ
Batsakis
J G
JG
Lippman
S M
SM
D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000517:prevention & control*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000517:prevention & control; D006801:Humans; D015474:Isotretinoin / Q000494:pharmacology / Q000627:therapeutic use*; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome; D019207:beta Carotene / Q000494:pharmacology / Q000627:therapeutic use*
D016588:Anticarcinogenic Agents; D019207:beta Carotene; D015474:Isotretinoin